|
1
|
Caronia D, Patiño-Garcia A, Peréz-Martínez
A, et al: Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma
survival after chemotherapy: a pharmacogenetic study. PLoS One.
6:e260912011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Balladelli A, Palmerini E, et al:
Neoadjuvant chemotherapy for osteosarcoma of the extremities in
preadolescent patients: the Rizzoli Institute experience. J Pediatr
Hematol Oncol. 30:908–912. 2008. View Article : Google Scholar
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorlick R, Anderson P, Andrulis I, et al:
Biology of childhood osteogenic sarcoma and potential targets for
therapeutic development: meeting summary. Clin Cancer Res.
9:5442–5453. 2003.PubMed/NCBI
|
|
5
|
Mérino D, Lalaoui N, Morizot A, Solary E
and Micheau O: TRAIL in cancer therapy: present and future
challenges. Expert Opin Ther Targets. 11:1299–1314. 2007.
|
|
6
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Almasan A and Ashkenazi A: Apo2L/TRAIL:
apoptosis signaling, biology, and potential for cancer therapy.
Cytokine Growth Factor Rev. 14:337–348. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: the potential of
recombinant human apoptosis ligand 2/Tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar
|
|
9
|
Walczak H, Miller RE, Ariail K, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganten TM, Haas TL, Sykora J, et al:
Enhanced caspase-8 recruitment to and activation at the DISC is
critical for sensitisation of human hepatocellular carcinoma cells
to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death
Differ. 11(Suppl 1): S86–S96. 2004. View Article : Google Scholar
|
|
11
|
Gómez-Benito M, Martinez-Lorenzo MJ, Anel
A, Marzo I and Naval J: Membrane expression of DR4, DR5 and
caspase-8 levels, but not Mcl-1, determine sensitivity of human
myeloma cells to Apo2L/TRAIL. Exp Cell Res. 313:2378–2388.
2007.PubMed/NCBI
|
|
12
|
Schuchmann M, Schulze-Bergkamen H,
Fleischer B, et al: Histone deacetylase inhibition by valproic acid
down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards
CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol
Rep. 15:227–230. 2006.
|
|
13
|
He SQ, Rehman H, Gong MG, et al:
Inhibiting survivin expression enhances TRAIL-induced tumoricidal
activity in human hepatocellular carcinoma via cell cycle arrest.
Cancer Biol Ther. 6:1247–1257. 2007.
|
|
14
|
Han J, Goldstein LA, Gastman BR and
Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of
TRAIL-mediated mitochondrial apoptosis. J Biol Chem.
281:10153–10163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bortul R, Tazzari PL, Cappellini A, et al:
Constitutively active Akt1 protects HL60 leukemia cells from
TRAIL-induced apoptosis through a mechanism involving NF-kappaB
activation and cFLIP(L) up-regulation. Leukemia. 17:379–389. 2003.
View Article : Google Scholar
|
|
16
|
Bosch FX, Ribes J and Borras J:
Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winfield LL and Payton-Stewart F:
Celecoxib and Bcl-2: emerging possibilities for anticancer drug
design. Future Med Chem. 4:361–383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei D, Wang L, He Y, et al: Celecoxib
inhibits vascular endothelial growth factor expression in and
reduces angiogenesis and metastasis of human pancreatic cancer via
suppression of Sp1 transcription factor activity. Cancer Res.
64:2030–2038. 2004. View Article : Google Scholar
|
|
19
|
Jeon YW and Suh YJ: Synergistic apoptotic
effect of celecoxib and luteolin on breast cancer cells. Oncol Rep.
29:819–825. 2013.PubMed/NCBI
|
|
20
|
Mikuła-Pietrasik J, Kuczmarska A, Kucińska
M, et al: Resveratrol and its synthetic derivatives exert opposite
effects on mesothelial cell-dependent angiogenesis via modulating
secretion of VEGF and IL-8/CXCL8. Angiogenesis. 15:361–376.
2012.PubMed/NCBI
|
|
21
|
Yoshida S, Amano H, Hayashi I, et al:
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis
and tumor growth in vivo. Lab Invest. 83:1385–1394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Zou Y, Mao Y, et al: Preclinical
toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats
and cynomolgus monkeys. Regul Toxicol Pharmacol. 61:230–235. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ashkenazi A: Targeting death and decoy
receptors of the tumour-necrosis factor superfamily. Nat Rev
Cancer. 2:420–430. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koschny R, Walczak H and Ganten TM: The
promise of TRAIL - potential and risks of a novel anticancer
therapy. J Mol Med (Berl). 85:923–935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cuello M, Ettenberg SA, Nau MM and
Lipkowitz S: Synergistic induction of apoptosis by the combination
of trail and chemotherapy in chemoresistant ovarian cancer cells.
Gynecol Oncol. 81:380–390. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagane M, Pan G, Weddle JJ, et al:
Increased death receptor 5 expression by chemotherapeutic agents in
human gliomas causes synergistic cytotoxicity with tumor necrosis
factor-related apoptosis-inducing ligand in vitro and in vivo.
Cancer Res. 60:847–853. 2000.
|
|
27
|
Gaiser T, Becker MR, Habel A, et al:
TRAIL-mediated apoptosis in malignant glioma cells is augmented by
celecoxib through proteasomal degradation of survivin. Neurosci
Lett. 442:109–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu G, Liu Y, Ji B, et al: Synergistic
effect of celecoxib on TRAIL-induced apoptosis in hepatocellular
carcinoma cells. Cancer Invest. 28:629–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ullah MF: Cancer multidrug resistance
(MDR): a major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
30
|
Irie T, Tsujii M, Tsuji S, et al:
Synergistic antitumor effects of celecoxib with 5-fluorouracil
depend on IFN-gamma. Int J Cancer. 121:878–883. 2007. View Article : Google Scholar : PubMed/NCBI
|
